Universal Treatment Protocols
ME/CFS research has identified treatment strategies with potential applicability across the full spectrum of post-viral, autoimmune, mitochondrial, and dysautonomic conditions. The protocols below represent evidence-based approaches that address fundamental shared pathophysiology rather than condition-specific symptoms. Critical caveat: These protocols are derived from ME/CFS research and clinical experience. Direct application to other conditions requires:
- Physician supervision and approval
- Condition-specific contraindication screening
- Individualized dosing based on severity and comorbidities
- Monitoring for adverse effects
- Recognition that evidence quality varies by condition
1 Comprehensive Mitochondrial Support
1.1 Rationale and Mechanism
Mitochondrial dysfunction is documented in ME/CFS (Wang et al. 2023) (Syed et al. 2025); analogous findings have been reported in Long COVID (Wu, Guzmán-Vélez, et al. 2025), fibromyalgia (Cordero et al. 2013), and other chronic fatigue conditions (Parikh et al. 2009). The comprehensive mitochondrial support stack addresses multiple points of failure:
Electron transport chain support: CoQ10 (shuttles electrons from Complex I and Complex II to Complex III), NADH (electron donor to Complex I)
ATP synthesis cofactors: D-ribose (substrate), magnesium (ATPase cofactor)
Oxidative stress protection: Alpha-lipoic acid (mitochondrial antioxidant; see Chapter Supplements and Nutraceuticals). Optional additions: vitamin E (membrane antioxidant) and phosphatidylcholine (membrane repair)—these are not reviewed individually in this text and lack ME/CFS-specific evidence; inclusion is based on theoretical rationale only
Fatty acid transport: Acetyl-L-carnitine (mitochondrial fatty acid oxidation)
NAD+ restoration: Nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN)
Citric acid cycle support: B-complex vitamins (B1, B2, B3, B5) Evidence base:
ME/CFS: CoQ10 + NADH demonstrated significant improvements in cognitive fatigue, overall fatigue, and sleep parameters in the largest RCT (Castro-Marrero 2021, n=207) (Castro-Marrero et al. 2021); an earlier smaller trial (Castro-Marrero 2015, n=73) showed improvements in fatigue and biochemical parameters (Castro-Marrero et al. 2015)
Long COVID: NR 2000 mg/day increased NAD+ levels 2.6–3.1 fold (Wu 2025, n=58) (Wu, Guzmán-Vélez, et al. 2025)
Fibromyalgia: CoQ10 300 mg/day reduced pain and fatigue (Cordero 2013, n=20) (Cordero et al. 2013)
Mitochondrial disorders: Established therapeutic role for CoQ10, ribose, carnitine (Parikh et al. 2009)
1.2 Protocol Details
Core stack (evidence-based dosing):
Coenzyme Q10: 100–300 mg/day typical (ubiquinol form preferred; RCT dose 200 mg; up to 400–600 mg in studies)
D-ribose: 5g TID (15g/day total), dissolved in water, taken with meals
NADH: 10–20mg/day, sublingual or enteric-coated
Acetyl-L-carnitine: 500–2000 mg/day, divided doses (start low; see Chapter Supplements and Nutraceuticals)
Alpha-lipoic acid: 300–600 mg/day (R-lipoic acid form preferred; start at 100–150 mg in ME/CFS and titrate—sensitive patients may experience paradoxical worsening (increased fatigue, malaise, or gastrointestinal symptoms) at higher initial doses; clinical observation)
Magnesium glycinate: 200–600 mg/day elemental (divided doses to avoid diarrhea; see Chapter Supplements and Nutraceuticals)
B-complex: High-potency formulation with methylated forms (B12 as methylcobalamin) Advanced additions:
Nicotinamide riboside (NR): 300–1000 mg/day (morning dosing; the only RCT-tested dose is 2000 mg/day (Wu, Guzmán-Vélez, et al. 2025); see Chapter Supplements and Nutraceuticals)
Pyrroloquinoline quinone (PQQ): 10–20 mg/day (mitochondrial biogenesis)
Creatine monohydrate: 3–5 g/day (ATP buffering, cognitive support)
1.3 Implementation Strategy
Titration: Start with 25–50% of target doses, increase weekly (clinical experience; no controlled titration protocol data). Introduce supplements one at a time per Chapter Supplements and Nutraceuticals, Section Practical Supplement Protocols; apply this titration to each supplement individually as it is added
Timing: Split doses throughout day; CoQ10 and fat-soluble nutrients with meals
Response monitoring: Track energy levels, cognitive function, post-exertional symptoms
Minimum trial duration: 8–12 weeks per individual supplement (mitochondrial adaptations require time). With sequential introduction (1–2 weeks between additions per Chapter Supplements and Nutraceuticals), the full stack requires substantially longer
Responder identification: Responder rates have not been established in controlled trials; clinical experience suggests some patients improve, but no reliable proportion can be cited. Non-responders may have different rate-limiting pathology Safety considerations:
CoQ10: May reduce warfarin effectiveness—the mechanism may involve enhanced CYP450-mediated warfarin hydroxylation (Zhou, Zhou, and Chan 2005); a structural similarity to vitamin K has also been proposed but is less well-documented. Monitor INR closely with physician guidance; see Chapter Supplements and Nutraceuticals, Section D-Ribose Evidence Quality
Alpha-lipoic acid: Monitor glucose in diabetics (insulin-sensitizing effect)
Carnitine: May theoretically lower seizure threshold in pre-existing epilepsy; consult physician (no controlled data; clinical caution). Also inhibits thyroid hormone nuclear uptake—patients on thyroid replacement should monitor thyroid function (Benvenga et al. 2001); see Chapter Supplements and Nutraceuticals, Section D-Ribose Evidence Quality for additional drug interactions
Magnesium: Dose-dependent diarrhea; reduce dose or switch to magnesium threonate
NR/NMN: Theoretical concern about NAD+ promoting tumor growth—rapidly proliferating cancer cells may exploit elevated NAD+ for energy and DNA repair (Palmer and Vaccarezza 2021). Avoid in active cancer; consult oncologist before use in patients with cancer history
1.4 Cross-Condition Applications
High priority for mitochondrial support:
Long COVID with persistent fatigue
Cancer-related fatigue (post-treatment, not during active treatment; see NR/NMN safety note above)
Fibromyalgia with exercise intolerance
POTS with fatigue predominance
Primary mitochondrial disorders (adjunct to genetic-specific therapy)
Neurodegenerative diseases (Parkinson’s, early Alzheimer’s) Lower priority (less evidence):
Autoimmune conditions without fatigue
MCAS (unless significant fatigue component)
Metabolic syndrome (focus on lifestyle first)
2 Autonomic-Catecholamine Restoration
2.1 Rationale and Mechanism
Catecholamine dysfunction affects POTS, dysautonomia, ME/CFS with orthostatic intolerance, and conditions with autonomic neuropathy (Campen et al. 2020). The restoration protocol addresses:
Substrate availability: L-tyrosine (precursor for dopamine → norepinephrine → epinephrine)
Cofactor sufficiency: Tetrahydrobiopterin (BH4), vitamin C, copper
Methylation support: SAMe, methylated B-vitamins (for catecholamine metabolism)
Adrenal support: Vitamin B5 (pantothenic acid), adaptogenic herbs Evidence base:
POTS: L-tyrosine improved orthostatic tolerance (case reports, small studies)
ME/CFS: BH4 elevation correlates with orthostatic intolerance (Bulbule et al. 2024)
Dysautonomia: Vitamin C supports catecholamine synthesis (May et al. 2013)
Adrenal insufficiency: B5 deficiency impairs cortisol synthesis
2.2 Protocol Details
Core interventions:
L-tyrosine: 500–1500mg/day, morning and midday (empty stomach for absorption)
Vitamin C: 1000–2000mg/day (cofactor for dopamine \(\beta\)-hydroxylase)
Vitamin B6 (P5P): 50–100mg/day (cofactor for aromatic L-amino acid decarboxylase)
Methylfolate: 1–5mg/day (methylation pathway support)
Methylcobalamin (B12): 1000–5000mcg/day sublingual
Pantothenic acid (B5): 500–1000mg/day (adrenal cortex support) Advanced additions:
Sapropterin (Tetrahydrobiopterin, BH4): 5–10mg/kg/day (prescription; for documented BH4 deficiency)
SAMe: 400–800mg/day (methylation, catecholamine metabolism)
Copper: 2mg/day (cofactor for dopamine \(\beta\)-hydroxylase; only if deficient)
Adaptogens: Rhodiola rosea 200–400mg, ashwagandha 300–600mg (adrenal support)
2.3 Implementation Strategy
Baseline assessment: Orthostatic vital signs, symptom severity scores
Tyrosine titration: Start 500mg/day, increase to 1500mg over 2 weeks
Timing: Morning and early afternoon (avoid evening due to potential sleep disruption)
Response monitoring: Orthostatic tolerance, brain fog, energy, heart rate variability
Trial duration: 4–8 weeks minimum Safety considerations:
Contraindications: Hyperthyroidism (tyrosine is thyroid hormone precursor), MAO inhibitors
Warnings: May worsen anxiety or insomnia in susceptible individuals
Monitoring: Blood pressure (may increase in some patients)
Drug interactions: Levodopa (competes for absorption), thyroid medications
2.4 Cross-Condition Applications
High priority:
POTS with low norepinephrine or hyperadrenergic subtype
ME/CFS with orthostatic intolerance
Dysautonomia (diabetic, autoimmune, idiopathic)
Long COVID with autonomic dysfunction
EDS with POTS Moderate priority:
Fibromyalgia with brain fog
Neurodegenerative diseases (Parkinson’s - with caution due to levodopa interactions)
3 Mast Cell Stabilization
3.1 Rationale and Mechanism
Mast cell activation contributes to ME/CFS, MCAS, EDS, POTS, Long COVID, and potentially fibromyalgia (Wirth and Scheibenbogen 2023) (Afrin et al. 2016). Stabilization strategies target:
Histamine blockade: H1 + H2 receptor antagonism (dual pathway)
Membrane stabilization: Cromolyn sodium, quercetin
PAF inhibition: Rupatadine (H1 + PAF dual action)
Mediator degradation: DAO supplementation for histamine
Trigger avoidance: Dietary histamine, stress, temperature extremes Evidence base:
MCAS: H1+H2 combination superior to monotherapy (Afrin et al. 2016)
ME/CFS: Rupatadine improved fatigue and orthostatic symptoms (clinical observations)
EDS: High prevalence of mast cell activation; stabilization improves GI symptoms (Seneviratne, Maitland, and Afrin 2017)
Long COVID: Antihistamines improved symptoms in observational studies
3.2 Protocol Details
First-line (H1 + H2 combination):
H1 antagonist: Cetirizine 10–20mg/day OR loratadine 10–20mg/day OR fexofenadine 180mg/day
H2 antagonist: Famotidine 20–40mg BID OR ranitidine 150mg BID (if available)
Rationale: Dual blockade addresses both H1 (allergic symptoms) and H2 (GI, vascular) pathways Advanced interventions:
Rupatadine: 10–20mg/day (H1 + PAF inhibition; superior to single-mechanism antihistamines)
Cromolyn sodium: 200mg QID oral (membrane stabilizer; prescription)
Ketotifen: 1–4mg/day (potent stabilizer; may cause sedation)
Quercetin: 500–1000mg BID (natural flavonoid stabilizer)
DAO supplementation: 10,000–20,000 HDU before meals (histamine degradation)
Vitamin C: 1000mg BID (natural antihistamine, mast cell stabilizer) Dietary modifications:
Low-histamine diet (avoid aged cheeses, fermented foods, alcohol, leftover meat)
DAO-rich foods (fresh meat, eggs)
Avoid histamine liberators (citrus, strawberries, tomatoes, chocolate)
Trial duration: 4–6 weeks
3.3 Implementation Strategy
Start conservative: H1 + H2 combination for 2–4 weeks
Add stabilizers: If partial response, add quercetin or cromolyn
Consider rupatadine: If standard antihistamines insufficient
Dietary trial: Implement low-histamine diet concurrently
Response monitoring: Symptom diary (flushing, GI symptoms, orthostatic tolerance, brain fog) Safety considerations:
First-generation antihistamines: Avoid (diphenhydramine, hydroxyzine) due to anticholinergic effects and cognitive impairment
Ketotifen: Significant sedation; start low (0.5–1mg) and titrate
Cromolyn: GI side effects common; take 15–30 minutes before meals
Drug interactions: H2 blockers may affect absorption of pH-dependent medications
3.4 Cross-Condition Applications
High priority:
MCAS (primary indication)
EDS with MCAS features
POTS with flushing or GI symptoms
ME/CFS with orthostatic intolerance and MCAS overlap
Long COVID with allergic/inflammatory symptoms Moderate priority:
Fibromyalgia with food sensitivities
Migraine with histamine trigger pattern
4 Neuroinflammation Reduction
4.1 Rationale and Mechanism
Neuroinflammation contributes to ME/CFS, Long COVID, fibromyalgia, neurodegenerative diseases, and potentially autoimmune conditions (Tate et al. 2022). Reduction strategies target:
Microglial modulation: Low-dose naltrexone (LDN)
Lipid mediators: Omega-3 fatty acids (EPA/DHA)
NF-\(\kappa\)B inhibition: Curcumin, resveratrol
Vagal stimulation: Non-invasive VNS, deep breathing
BBB protection: Luteolin, apigenin Evidence base:
ME/CFS: LDN 4.5mg improved pain and fatigue in 65% (Younger 2013, n=80) (Younger, Parkitny, and McLain 2014a)
Long COVID: Omega-3 2g/day reduced inflammatory markers (pilot data)
Fibromyalgia: LDN reduced pain scores by 30% (Parkitny 2014, meta-analysis) (Younger, Parkitny, and McLain 2014b)
Alzheimer’s: Curcumin reduced amyloid burden (preclinical, limited human data)
4.2 Protocol Details
Core interventions:
Low-dose naltrexone (LDN): 1.5–4.5mg at bedtime (prescription; compounded)
- Start 1.5mg, increase by 1mg every 2 weeks to 4.5mg
- Mechanism: Transient opioid receptor blockade → increased endorphin production, microglial modulation
- Response time: 8–12 weeks for full effect
Omega-3 fatty acids: 2–4g/day combined EPA+DHA
- High EPA:DHA ratio (2:1 or 3:1) preferred for anti-inflammatory effect
- Triglyceride form better absorbed than ethyl ester
Curcumin: 500–1000mg BID (with black pepper/piperine for bioavailability)
- Use liposomal or phytosome formulations for enhanced absorption Advanced additions:
Luteolin: 100–200mg/day (microglial inhibitor, BBB permeable)
Resveratrol: 200–500mg/day (SIRT1 activator, anti-inflammatory)
Palmitoylethanolamide (PEA): 600–1200mg/day (endocannabinoid modulator)
Alpha-lipoic acid: 600mg/day (NF-\(\kappa\)B inhibition, crosses BBB) Non-pharmacological:
Vagal nerve stimulation: Non-invasive transcutaneous VNS devices (gammaCore, Parasym)
Breathing exercises: Slow diaphragmatic breathing (5–6 breaths/min) for 10–20 min BID
Cold exposure: Brief cold showers (vagal activation, anti-inflammatory)
4.3 Implementation Strategy
Start with LDN: Highest evidence base; titrate slowly to minimize side effects
Add omega-3: Immediate start (safe, broad benefits)
Layer curcumin: After 4 weeks if partial response
Consider advanced agents: If inadequate response after 8–12 weeks
Response monitoring: Pain scores, cognitive function, sleep quality, overall well-being Safety considerations:
LDN contraindications: Active opioid use (precipitates withdrawal), liver disease
LDN side effects: Vivid dreams (dose-dependent), insomnia (switch to morning dosing)
Omega-3: Bleeding risk at high doses (>3g/day); caution with anticoagulants
Curcumin: May potentiate anticoagulants; GI upset in sensitive individuals
Resveratrol: May interact with blood thinners
4.4 Cross-Condition Applications
High priority:
ME/CFS with pain and cognitive dysfunction
Fibromyalgia (LDN well-established)
Long COVID with neurological symptoms
Autoimmune conditions with CNS involvement (MS, lupus cerebritis) Moderate priority:
Neurodegenerative diseases (adjunct therapy)
POTS with brain fog
Cancer-related fatigue (LDN may modulate cancer-related inflammation)
5 GPCR Autoantibodies as Clinical Biomarkers Across POTS, ME/CFS, and Long COVID
{{/* D40: IgG1/IgG4 subclass pathogenicity (Tier 1, cert 0.50) — placed here as speculation /}} {{/ D36: Composite neuroimmune panel (Tier 1, cert 0.45) */}}
6 Energy Envelope Management (Pacing)
6.1 Rationale and Mechanism
Energy envelope management (pacing) prevents post-exertional symptom exacerbation across ME/CFS, Long COVID, POTS, fibromyalgia, and any condition with exercise intolerance (Jason et al. 2009). The approach addresses:
Anaerobic threshold violation: Staying within aerobic capacity prevents PEM
Boom-bust cycles: Consistent activity prevents overexertion followed by crashes
Circadian optimization: Aligning activity with natural energy fluctuations
Recovery prioritization: Adequate rest prevents accumulated deficits Evidence base:
ME/CFS: Pacing superior to graded exercise therapy (PACE trial reanalysis) (Wilshire et al. 2018)
Long COVID: Activity management improved function vs. push-through approach
POTS: Heart rate-based exercise limits improved outcomes vs. standard exercise
Fibromyalgia: Pacing reduced pain flares and improved consistency
6.2 Protocol Details
Core principles:
Establish baseline: Identify current sustainable activity level (what you can do consistently without symptom worsening)
Stay within envelope: Operate at 70–80% of baseline on average (leave margin for fluctuations)
Monitor intensity: Use heart rate, perceived exertion, symptom tracking
Avoid boom-bust: Resist temptation to “cash in” on good days with excessive activity
Gradual expansion: Increase activity by 5–10% every 2–4 weeks if sustained improvement Heart rate monitoring approach:
Calculate anaerobic threshold (AT):
- Conservative method: (220 - age) × 0.6
- Workwell Foundation formula: (220 - age) × 0.55 for severe ME/CFS
- 2-day CPET testing (gold standard but not widely available)
Activity limits: Keep heart rate below AT during all activities
Wearable devices: Continuous HR monitors (Polar, Garmin, Apple Watch) with alerts
Rest breaks: When approaching AT, stop activity immediately and rest until HR normalizes Activity structuring:
Time-based limits: Cap activities at 10–15 minute intervals with rest breaks
Task modification: Break complex tasks into smaller components
Energy accounting: Track “energy expenditure” throughout day
Pre-planning: Schedule high-priority activities during peak energy windows
Rest is active treatment: Schedule rest periods, not just “what’s left over” Symptom monitoring:
Daily symptom diary (fatigue, pain, cognitive function, PEM severity)
Activity log (duration, intensity, heart rate data)
Identify personal triggers and patterns
Adjust envelope boundaries based on data, not motivation
6.3 Implementation Strategy
- Assessment phase (2–4 weeks):
- Track current activity and symptoms without modification
- Identify baseline capacity and PEM triggers
- Calculate heart rate threshold
- Stabilization phase (4–8 weeks):
- Reduce activity to 70–80% of baseline
- Implement heart rate monitoring
- Eliminate boom-bust cycles
- Goal: Consistent symptom stability
- Expansion phase (ongoing):
- Increase activity by 5–10% every 2–4 weeks
- Monitor for PEM after each increase
- Pull back immediately if symptoms worsen
- Expansion may take months to years Common pitfalls:
- Underestimating cognitive activity: Mental exertion counts toward energy envelope
- Ignoring emotional stress: Stress depletes energy reserves
- Good-day overexertion: Most common cause of relapse
- External pressure: Family/employer expectations pushing beyond envelope
- Deconditioning fear: Accepting current limits is not “giving up”
6.4 Cross-Condition Applications
High priority (exercise intolerance present):
ME/CFS (cornerstone of management)
Long COVID with PEM
POTS with exercise intolerance
Fibromyalgia with pain flares
Post-viral fatigue syndromes Moderate priority:
Cancer-related fatigue during treatment
Autoimmune conditions with fatigue
Heart failure (already uses heart rate-based exercise limits) Low priority / not applicable:
Conditions without exercise intolerance
Deconditioning without pathological exercise response (standard exercise progression appropriate) Critical distinction: Pacing is for pathological exercise intolerance (PEM), NOT simple deconditioning. Standard graded exercise therapy appropriate for deconditioning; harmful for PEM.
7 Clinical Trial Opportunities
- Daratumumab in Long COVID: Phase 2 trial in patients with elevated GPCR autoantibodies
- Rupatadine in EDS-POTS-MCAS: Test triple-action (H1 + PAF + mast cell stabilizer) vs. standard antihistamines
- NAD+ precursors in cancer-related fatigue: Extend Long COVID NR findings
- Catecholamine synthesis support in POTS: L-tyrosine + Tetrahydrobiopterin (BH4) cofactors vs. placebo
- Comprehensive mitochondrial support in fibromyalgia: Test full stack vs. individual components